phenox® GmbH has been granted CE Mark approval for pREset® LITE Thrombectomy Device for commercialization within the European Union and any country that accepts CE Mark approval. With the pREset LITE phenox expands its innovative product portfolio by offering physicians new options for the intracranial treatment of ischemic stroke.

Dr.-Ing. Hermann Monstadt, Managing Director at phenox GmbH, comments, “the pREset LITE has been developed to enable physicians treating ischemic stroke even in the very distal and therefore very sensitive area of the brain."

continue reading